ARK ETF Trust - ARK Genomic Revolution ETF (LON:0CQL)

Assets	745.48M
Expense Ratio	0.75%
PE Ratio	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-6.47%

Volume	393
Open	25.26
Previous Close	25.22
Day's Range	25.00 - 25.37
52-Week Low	17.25
52-Week High	31.12
Beta	n/a
Holdings	37
Inception Date	Oct 31, 2014

About 0CQL

ARK ETF Trust - ARK Genomic Revolution ETF is an exchange traded fund launched and managed by ARK Investment Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across diversified sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental and quantitative analysis with bottom-up and top-down stock picking approach to create its portfolio. It benchmarks the performance of its portfolio against the NASDAQ Healthcare Index, the S&P 500 Index and the MSCI World Index. The fund employs internal and external research to create its portfolio. ARK ETF Trust - ARK Genomic Revolution ETF was formed on October 31, 2014 and is domiciled in the United States.

• Asset Class: Equity
• Category: Theme
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0CQL
• Provider: ARK

Performance

0CQL had a total return of -6.47% in the past year, including dividends. Since the fund's inception, the average annual return has been -0.22%.

Top 10 Holdings

57.35% of assets

Name	Symbol	Weight
Tempus AI, Inc.	TEM	11.87%
CRISPR Therapeutics AG	CRSP	9.46%
Twist Bioscience Corporation	TWST	5.83%
Recursion Pharmaceuticals, Inc.	RXRX	5.33%
Guardant Health, Inc.	GH	4.73%
Natera, Inc.	NTRA	4.46%
10x Genomics, Inc.	TXG	4.35%
Adaptive Biotechnologies Corporation	ADPT	3.97%
Personalis, Inc.	PSNL	3.68%
Schrödinger, Inc.	SDGR	3.67%